Biogen Inc. (BIIB)
NASDAQ · Health Care · market cap 28.94B
Share price
$249.01
At the last nightly close
Intrinsic value
$291.74
A single conservative estimate.
Margin of safety
+17.2%
($291.74 − $249.01) ÷ $249.01
EV / EBIT
13.8
On the median operating profit of 15 fiscal years through 2025.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above starts from the lower of the first two; the Graham Number never enters it.
The frame gives no credit for growth unless the company has earned it: only a return on invested capital that has beaten the cost of capital year after year earns a growth credit, and that credit is capped. A company that compounds will therefore usually read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-11-02.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2025-FY | 9.89B | 2.47B | 1.29B | 8.83 | 1.97B |
| 2024-FY | 9.68B | 2.28B | 1.63B | 11.21 | 2.52B |
| 2023-FY | 9.84B | 1.85B | 1.16B | 8.02 | 1.24B |
| 2022-FY | 10.17B | 2.90B | 3.05B | 20.96 | 1.14B |
| 2021-FY | 10.98B | 2.84B | 1.56B | 10.40 | 3.38B |
Filed figures from SEC EDGAR, in the reporting currency.
Next earnings
Recent news
- BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300finance.yahoo.com
- Biogen (BIIB) Stock Price, News & Analysismarketbeat.com
- BIIB Stock Earnings Preview: What’s Next for Biogen as its MS Business Wanes? | CMC Marketscmcmarkets.com
- Biogen (BIIB) Earnings: Latest Report, Earnings Call & Financialspublic.com
- Biogen Inc. (BIIB) Latest Stock News & Headlines - Yahoo Financefinance.yahoo.com
Headlines link to their source. Sperio does not republish article text.
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on BIIB.
Run the board on BIIB10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.